Evaluation of TorsinA as a Target for Parkinson Disease Therapy in Mouse Models

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Li, Xinru ^a   Lee, Jenny ^a   Parsons, Dee ^a   Janaurajs, Karen ^a   Standaert, David G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CHAPERONE; CRE RECOMBINASE; PARVOVIRUS VECTOR; TORSINA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE DELETION; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TORSINA GENE; TRANSGENIC MOUSE; VIRAL GENE THERAPY; WESTERN BLOTTING; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOVIRIDAE; ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; INTEGRASES; LEWY BODIES; MALE; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

ADENO-ASSOCIATED VIRUS; ANIMALIA; INVERTEBRATA; MUS; MUS MUSCULUS;

EID: 84869756871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050063     Document Type: Article

References (26)

1. Yacoubian TA, Standaert DG (2008) Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta.
2. Standaert DG, Yacoubian TA, (2010) Target validation: the Parkinson disease perspective. Dis Model Mech 3: 259-262.
3. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, et al. (1997) The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics 17: 40-48.
4. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, et al. (2008) The pathophysiological basis of dystonias. Nat Rev Neurosci 9: 222-234.
5. Standaert DG, (2011) Update on the pathology of dystonia. Neurobiol Dis 42: 148-151.
6. Breakefield XO, Kamm C, Hanson PI, (2001) TorsinA: movement at many levels. Neuron 31: 9-12.
7. Naismith TV, Heuser JE, Breakefield XO, Hanson PI, (2004) TorsinA in the nuclear envelope. Proc Natl Acad Sci U S A 101: 7612-7617.
8. Goodchild RE, Dauer WT (2004) Mislocalization to the nuclear envelope: An effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci U S A.
9. Goodchild RE, Dauer WT, (2005) The AAA+ protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. J Cell Biol 168: 855-862.
10. Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO, (2006) Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol Dis 22: 98-111.
11. Torres GE, Sweeney AL, Beaulieu JM, Shashidharan P, Caron MG, (2004) Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc Natl Acad Sci U S A 101: 15650-15655.
12. Cao S, Gelwix CC, Caldwell KA, Caldwell GA, (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 25: 3801-3812.
13. Augood SJ, Penney JB, Friberg IK, Breakefield XO, Young AB, et al. (1998) Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology 46: 669-673.
14. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, et al. (2001) A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol 159: 339-344.
15. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, et al. (2002) TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 83: 846-854.
16. Jackson-Lewis V, Przedborski S, (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151.
17. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, et al. (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 100: 1449-1457.
18. Yokoi F, Dang MT, Mitsui S, Li J, Li Y, (2008) Motor deficits and hyperactivity in cerebral cortex-specific Dyt1 conditional knockout mice. J Biochem 143: 39-47.
19. Scammell TE, Arrigoni E, Thompson MA, Ronan PJ, Saper CB, et al. (2003) Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J Neurosci 23: 5762-5770.
20. Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, et al. (2005) Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci 25: 5351-5355.
21. Zhao Y, DeCuypere M, LeDoux MS, (2008) Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp Neurol 210: 719-730.
22. Przedborski S, Tieu K, Perier C, Vila M, (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379.
23. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L, (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025.
24. Dawson TM, Ko HS, Dawson VL, (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661.
25. Ulusoy A, Decressac M, Kirik D, Bjorklund A, (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res 184: 89-111.
26. Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, et al. (2007) Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 102: 783-788.